TY - JOUR
T1 - Prevention of solely estrogen-induced mammary tumors in female ACI rats by tamoxifen
T2 - Evidence for estrogen receptor mediation
AU - Li, S. A.
AU - Weroha, S. J.
AU - Tawfik, O.
AU - Li, J. J.
PY - 2002/11/1
Y1 - 2002/11/1
N2 - There is increasing evidence that both endogenous and exogenously ingested estrogens play a primary role in sporadic breast cancer causation. To establish further that solely estrogen-induced mammary oncogenesis in female ACI rats is an estrogen receptor (ERα)-driven process, we show for the first time that concomitant treatment with the antiestrogen, tamoxifen citrate (TAMc), completely prevents the induction of 17β-estradiol (E2)-induced mammary gland tumors (MGTs). This finding is also supported by the reduced mammary gland (MG) lobulo-alveolar development and proliferative activity observed in TAMc+E2-treated animals compared with MGs from animals treated with E2 alone. These data also correlated with a marked decrease in the number of MG cells expressing ERα and progesterone receptor (PR) in immunostained MG tissue sections from TAMc+E2-treated animals. Additionally, a marked decline in the level of expression of ERα 47, 56 and 66 kDa forms, and PR-A and PR-B was seen in TAMc+E2-treated MGs, compared with MGs treated solely with E2. Thus, both ERα and PR MG profiles in TAMc+E2-treated rats essentially revert to their respective receptor profiles seen in untreated control and TAMc-alone-treated rats. The presence of 56 and 54 kDa isoforms in chronically E2-treated MGs and in MGTs respectively may contribute to fostering the enhanced E2-dependent growth response of both precursor and frank MGT epithelial cells. These findings are consistent with an ERα/PR-mediated MG cell proliferation, a prerequisite for generating the high frequency of chromosomal instability seen in E2-induced ductal carcinomas in situ and primary MGTs in female ACI rats reported by us previously.
AB - There is increasing evidence that both endogenous and exogenously ingested estrogens play a primary role in sporadic breast cancer causation. To establish further that solely estrogen-induced mammary oncogenesis in female ACI rats is an estrogen receptor (ERα)-driven process, we show for the first time that concomitant treatment with the antiestrogen, tamoxifen citrate (TAMc), completely prevents the induction of 17β-estradiol (E2)-induced mammary gland tumors (MGTs). This finding is also supported by the reduced mammary gland (MG) lobulo-alveolar development and proliferative activity observed in TAMc+E2-treated animals compared with MGs from animals treated with E2 alone. These data also correlated with a marked decrease in the number of MG cells expressing ERα and progesterone receptor (PR) in immunostained MG tissue sections from TAMc+E2-treated animals. Additionally, a marked decline in the level of expression of ERα 47, 56 and 66 kDa forms, and PR-A and PR-B was seen in TAMc+E2-treated MGs, compared with MGs treated solely with E2. Thus, both ERα and PR MG profiles in TAMc+E2-treated rats essentially revert to their respective receptor profiles seen in untreated control and TAMc-alone-treated rats. The presence of 56 and 54 kDa isoforms in chronically E2-treated MGs and in MGTs respectively may contribute to fostering the enhanced E2-dependent growth response of both precursor and frank MGT epithelial cells. These findings are consistent with an ERα/PR-mediated MG cell proliferation, a prerequisite for generating the high frequency of chromosomal instability seen in E2-induced ductal carcinomas in situ and primary MGTs in female ACI rats reported by us previously.
UR - http://www.scopus.com/inward/record.url?scp=11144221653&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=11144221653&partnerID=8YFLogxK
U2 - 10.1677/joe.0.1750297
DO - 10.1677/joe.0.1750297
M3 - Review article
C2 - 12429028
AN - SCOPUS:11144221653
SN - 0022-0795
VL - 175
SP - 297
EP - 305
JO - Journal of Endocrinology
JF - Journal of Endocrinology
IS - 2
ER -